Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor alpha blocker adalimumab in cryptococcal pneumonia.
Tumor necrosis factor alpha antagonists have proven efficacious for a variety of autoimmune-mediated diseases. However, recent data have highlighted the risk of invasive fungal infections with their use. These agents are typically discontinued when infectious complications occur during therapy; however, the immune reconstitution inflammatory syndrome (IRIS) may be seen after drug cessation. We describe the 1st case of IRIS secondary to cryptococcal pneumonia after cessation of adalimumab.
Cadena
Jose
J
Department of Medicine, University of Texas Health Science Center at San Antonio, 78229, USA.
Thompson
George R
GR
Ho
Tony T
TT
Medina
Edward
E
Hughes
Darrel W
DW
Patterson
Thomas F
TF
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003453:Cryptococcosis / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome; D007155:Immunologic Factors / Q000627:therapeutic use*; D008875:Middle Aged; D011014:Pneumonia / Q000150:complications* / Q000188:drug therapy; D028761:Withholding Treatment
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000068879:Adalimumab